There are  established clinical development programs for IGF1R inhibitors among patients with gastric or gastro-intestinal adenocarcinoma [107], but little has been done (from the clinical perspective) in the indication of ESCC. Here, IGF1R is linked to esophageal squamous cell carcinoma.